Microfluidic-Based Microinjectrode System for Combined Drug Infusion and Electrophysiology

Executive Industry Relevance

Simultaneous drug infusion and electrophysiological recording using a microfluidic-based microinjectrode system enables precise interrogation of neural circuits in vivo. This integrated approach supports mechanistic de-risking and target validation by allowing real-time assessment of compound effects on neural activity. The method enhances predictive confidence at the discovery and preclinical interface for CNS-targeted portfolios.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct testing of pharmacological hypotheses in live neural tissue.
• Supports functional target validation by correlating drug delivery with electrophysiological changes.
• Facilitates mechanistic de-risking through real-time neural response monitoring.

Screening & Assay Development

• Provides a validated system for quantitative measurement of neural activity during compound administration.
• Improves assay reproducibility by integrating precise volume tracking with electrophysiological readouts.
• Supports development of scalable, standardized protocols for CNS drug screening.

Translational & Preclinical Research

• Aligns preclinical models with disease-relevant neural endpoints for translational continuity.
• Enables risk-adjusted advancement decisions by linking drug exposure to functional neural outcomes.
• Supports identification of translational biomarkers based on electrophysiological signatures.

Pipeline & Workflow Integration

This microfluidic microinjectrode system bridges early discovery and preclinical research by enabling simultaneous drug delivery and neural recording in vivo.

• Discovery Biology: Supports hypothesis testing and pathway clarification through direct neural response measurement.
• Screening: Delivers quantitative, reproducible electrophysiological data for compound evaluation.
• Analytics: Provides real-time readouts of neural activity correlated with precise drug infusion volumes.
• Translational Research: Facilitates continuity from discovery to preclinical validation in CNS programs.
• Enterprise Reuse: Offers a reusable platform adaptable to various CNS targets and compounds.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in CNS drug discovery.
• Operational Value: Standardizes simultaneous drug delivery and neural recording workflows.
• Strategic Value: Improves go/no-go decisions and capital efficiency by linking compound action to neural endpoints.
• Portfolio Impact: Enables risk-adjusted prioritization of CNS assets based on functional validation.

Implementation Considerations

• Requires expertise in microfluidics, electrophysiology, and in vivo neuroscience techniques.
• Needs specialized instrumentation for microfluidic control and neural signal acquisition.
• Demands rigorous cross-team standardization for reproducible data generation.
• Adaptation across different animal models may require protocol optimization.
• Volume tracking and interface monitoring are critical for precise dosing and data integrity.

Biopharma FAQs